Donal McLornan, MBBCh, MRCP, PhD, FRCPath, explains the challenges of choosing optimal timing for allogeneic hematopoietic cell transplantation in myelofibrosis.
Donal McLornan, MBBCh, MRCP, PhD, FRCPath
Advertisement
Donal McLornan, MBBCh, MRCP, PhD, FRCPath, is a consultant, Hematology and Stem Cell Transplantation, University College London Hospitals NHS Foundation Trust.
Articles by Donal McLornan, MBBCh, MRCP, PhD, FRCPath
Donal McLornan, MBBCh, MRCP, PhD, FRCPath, discusses future research directions for an EBMT machine learning model for identifying and stratifying transplant risk in myelofibrosis.
Advertisement
Latest Updated Articles
Dr McLornan on the Future of an EBMT Machine Learning Model for Identifying and Stratifying Transplant Risk in MyelofibrosisPublished: April 3rd 2025 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
2
Iberdomide Plus Daratumumab/Dexamethasone Displays High Response Rates in NDMM
3
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
4
FDA Approval Tees Up T-DXd Plus Pertuzumab as a New SOC in HER2+ Breast Cancer
5